Key Takeaways
- Teva Canada will commercialize Opuviz in Canada under a license and commercialization agreement with Samsung Bioepis.
- Samsung Bioepis will remain responsible for registration and manufacture of the aflibercept biosimilar.
- Health Canada approved Opuviz in October 2025 for wet AMD, retinal vein occlusion–related macular edema, diabetic macular edema, and myopic choroidal neovascularization.
Teva and Samsung Bioepis have entered into a license and commercialization agreement for Opuviz (aflibercept), a biosimilar referencing Eylea (aflibercept, Regeneron), in Canada, the companies announced. Under the agreement, Samsung Bioepis is responsible for registration and manufacture of the product, and Teva Canada, a subsidiary of Teva Pharmaceutical Industries, is responsible for commercialization.
Opuviz received Health Canada approval in October 2025 and is indicated for the treatment of neovascular age-related macular degeneration, visual impairment resulting from macular edema secondary to central retinal vein occlusion or branch retinal vein occlusion, diabetic macular edema, and myopic choroidal neovascularization.
“This agreement is an important step in strengthening our biosimilars portfolio in Canada,” said Fabien Paquette, General Manager of Teva Canada, adding that it reflects the company’s aim to expand its ophthalmology footprint through strategic partnerships.
Samsung Bioepis’ aflibercept biosimilar is also available in Europe and the Republic of Korea. Teva Canada said it will provide details on the anticipated Canadian market launch of Opuviz at a later time.
